Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function

American Journal of Hematology

Volumn 84, Issue 3, 2009, Pages 167-169

  Okuda, Shinya ^a   Terasako, Kiriko ^a   Oshima, Kumi ^a   Sato, Miki ^a   Nakasone, Hideki ^a   Kako, Shinichi ^a   Yamazaki, Rie ^a   Tanaka, Yukie ^a   Tanihara, Aki ^a   Higuchi, Takakazu ^a   Nishida, Junji ^a   Kanda, Yoshinobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ESTRADIOL; FLUCONAZOLE; FLUDARABINE; FOLLITROPIN; LEVOFLOXACIN; LUTEINIZING HORMONE; METHOTREXATE; MORPHINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; CASE REPORT; CONTINUOUS INFUSION; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INFECTION PREVENTION; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MYCOSIS; MYELOABLATIVE CONDITIONING; OVARY FUNCTION; OVARY INSUFFICIENCY; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RADIATION DOSE; STOMATITIS; VIRUS INFECTION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MYELOABLATIVE AGONISTS; OVARY; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 62949115982     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21355     Document Type: Article

References (16)

1. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000;37:69-80.
2. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: A randomized controlled study of conditioning regimens. Blood 2007;109:4582-4585.
3. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006;108:1485-1491.
4. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Blood 2002;100:799-803.
5. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: A report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005;36:947-950.
6. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 1986;68:1114-1118.
7. Sanders JE. Growth and development after hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' Hematopoietic Cell Transplantation. Malden, MA, USA: Blackwell Science; 2004. pp 929-943.
8. Cheng YC, Saliba RM, Rondon G, et al. Reduced-intensity conditioning (RIC) regimens result in low prevalence of premature ovarian failure (POF) in women underwent hematopoietic stem-cell transplantation (HST). Biol Blood Marrow Transplant 2004;10(Suppl. 1):25-26.
9. Shank B, Hoppe RT. Radiotherapeutic principles of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' Hematopoietic Cell Transplantation. Malden, MA, USA: Blackwell Science; 2004. pp 178-197.
10. Nakagawa K, Kanda Y, Yamashita H, et al. Preservation of ovarian function by ovarian shielding when undergoing total body irradiation for hematopoietic stem cell transplantation: A report of two successful cases. Bone Marrow Transplant 2006;37:583-587.
11. Nakagawa K, Kanda Y, Yamashita H, et al. Ovarian shielding allows ovarian recovery and normal birth in female hematopoietic stem cell transplantation recipients undergoing total body irradiation. Bone Marrow Transplant 10.1038/bmt.2008.309.
12. Oshima K, Kanda Y, Nakasone H, et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 2008;83:226-232.
13. Kanda Y, Mineishi S, Saito T, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;28:689-692.
14. Asano-Mori Y, Kanda Y, Oshima K, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008;83:472-476.
15. Kanda Y, Mineishi S, Saito T, et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation. Transplantation 2002;73:568-572.
16. Thiede C, Florek M, Bornhauser M, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999;23:1055-1060.